A combined protocol with piroxicam, chemotherapy, and whole pelvic irradiation with simultaneous boost volumetric modulated arc radiotherapy for muscle-invasive canine urinary transitional cell carcinoma: First clinical experience

The Journal of Veterinary Medical Science

article

Luca MALFASSI¹  Mario DOLERA¹  Francesca FIDANZIO²  Massimo SALA¹  Silvia MARCARINI¹  Giovanni MAZZA¹  Nancy CARRARA¹  Simone PAVESI¹  Giacomo GNUDI²  Gaetano URSO³ 

[1] “La Cittadina” Foundation for Veterinary Studies and Research;Department of Veterinary Medical Science, University of Parma;Medical Physics Department, Local Health Authority of Lodi

关键词: chemotherapy;    dog;    piroxicam;    radiotherapy;    transitional cell carcinoma;   

DOI  :  10.1292/jvms.19-0662

学科分类：兽医学

来源: Japanese Society of Veterinary Science

【 摘 要 】

The aims of this pilot study were to evaluate the feasibility and efficacy of high-dose hypofractionated volumetric modulated arc radiotherapy (VMAT) applied to whole pelvic region radiotherapy (WPRT) with multilevel simultaneous integrated boost (MLSIB) combined with piroxicam and chemotherapy for the treatment of canine transitional cell carcinoma (TCC) of the lower urinary tract with muscle invasion TCC. Twelve dogs were enrolled, according to stage, in two groups: group 1, TCC confined to the urinary tract; group 2, TCC with metastasis. The planning target volume dose was tailored from 36 to 42 Gy in 6 fractions. All dogs were prescribed piroxicam and radiosensitizing carboplatin, and six received chemotherapy after radiotherapy. Serial follow-ups with computed tomography and magnetic resonance imaging were performed. Disease control and toxicity effects were evaluated according to the Response Evaluation Criteria in Solid Tumors and Veterinary Radiation Therapy Oncology Group criteria. The treatment was well tolerated, and no high-grade side effects were reported. The median overall survival times for groups 1 and 2 were 1,230 and 150 days, respectively. A considerable percentage of patients in group1 (50%) were still alive at the time of writing this paper, and a longer follow-up could enable a more accurate survival analysis. This preliminary analysis shows that VMAT applied to the WPRT with MLSIB is an effective and safe option for dogs with lower urinary TCC, although the presence of metastases worsens the prognosis.

【 授权许可】

Unknown